Affordable Access

deepdyve-link
Publisher Website

Prognostic value of PD-L1 expression on immune cells or tumor cells for locally advanced esophageal squamous cell carcinoma in patients treated with neoadjuvant chemoradiotherapy.

Authors
  • Huang, Ta-Chen1, 2
  • Liang, Cher-Wei3
  • Li, Yu-I3
  • Guo, Jhe-Cyuan2, 4
  • Lin, Chia-Chi2
  • Chen, Ya-Jhen1
  • Cheng, Ann-Lii5, 6, 7, 8
  • Hsu, Chih-Hung5, 6, 8
  • 1 Graduate Institute of Oncology, National Taiwan University College of Medicine, Taipei, Taiwan. , (Taiwan)
  • 2 Department of Oncology, National Taiwan University Hospital, Taipei, Taiwan. , (Taiwan)
  • 3 Department of Pathology, Fu-Jen Catholic University Hospital, New Taipei City, Taiwan. , (Taiwan)
  • 4 National Taiwan University Cancer Center, National Taiwan University College of Medicine, Taipei, Taiwan. , (Taiwan)
  • 5 Graduate Institute of Oncology, National Taiwan University College of Medicine, Taipei, Taiwan. [email protected] , (Taiwan)
  • 6 Department of Oncology, National Taiwan University Hospital, Taipei, Taiwan. [email protected] , (Taiwan)
  • 7 Department of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan. [email protected] , (Taiwan)
  • 8 National Taiwan University Cancer Center, National Taiwan University College of Medicine, Taipei, Taiwan. [email protected] , (Taiwan)
Type
Published Article
Journal
Journal of Cancer Research and Clinical Oncology
Publisher
Springer-Verlag
Publication Date
Jul 01, 2022
Volume
148
Issue
7
Pages
1803–1811
Identifiers
DOI: 10.1007/s00432-021-03772-7
PMID: 34432128
Source
Medline
Keywords
Language
English
License
Unknown

Abstract

Programmed death-ligand 1 (PD-L1) expression may influence the prognosis of patients with localized esophageal cancer. The current study compared the prognostic value of PD-L1 expression between tumor cells and immune cells. Archival esophageal tumor tissue samples were collected from patients who received paclitaxel and cisplatin-based neoadjuvant chemoradiotherapy (CRT) for locally advanced esophageal squamous cell carcinoma (ESCC) in three prospective phase II trials. PD-L1 expression on tumor and immune cells was examined immunohistochemically by using the SP142 antibody and scored by two independent pathologists. The association of PD-L1 expression with patient's outcomes was analyzed using a log-rank test and Cox regression multivariate analysis. A total of 100 patients were included. PD-L1 expression on tumor cells was positive (≥ 1%, TC-positive) in 55 patients; PD-L1 expression on immune cells was high (≥ 5%, IC-high) in 30 patients. TC-positive status was associated with poor overall survival (OS) (HR: 1.63, P = 0.035), whereas IC-high status was associated with improved OS (HR: 0.44, P = 0.0024). Multivariate analysis revealed that TC-positive, IC-high, and performance status were independent prognostic factors for progression-free survival and that IC-high and performance status were independent factors for OS. Furthermore, the combination of IC-high and TC-negative status was associated with the optimal OS, whereas that of TC-positive and IC-low status was associated with the worst OS. PD-L1 expression on tumor and immune cells may have different prognostic value for patients with locally advanced ESCC receiving neoadjuvant CRT. A combination of these two indexes may further improve the prognostic prediction. © 2021. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.

Report this publication

Statistics

Seen <100 times